Global Titans Brings the World’s First NFT Pay-Per-View Sports Event Live From the Helipad of Burj Al Arab, on May 14th, 2022
25.4.2022 17:40:00 EEST | Business Wire | Press release
ROQUMedia:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005564/en/
Mayweather Global Titans Poster (Photo: AETOSWire)
FLOYD MAYWEATHER:
https://twitter.com/FloydMayweather/status/1517594581373648896?s=20&t=dEEnqLrQWsybIa81CA-JJA
Global Titans Fight Series announced the WORLD’S FIRST EVER NFT SPORTS event will give access to an exclusive livestream pay-per-view for NFT ticket holders. The Global Titans NFT tickets are considered a historic moment, where sports and tech fans take a giant leap forward, changing the way one interacts with live entertainment.
The NFT ticket will give access to watch Global Titans Dubai live online on May 14th, where an epic night of boxing on the helipad of the iconic Burj Al Arab Jumeirah hotel. The spectacular event boasts an explosive line-up including star champions Floyd Mayweather, Anderson Silva and many more.
A landmark moment for international sports, fans buying the NFT will also acquire a special Global Titans NFT ticket, that is highly collectable. More than an event ticket, NFT technology provides buyers with unique features such as future access, rewards and more – all that increase the value of its ownership long after the event.
Developing special technologies, ROQUMedia and Yakomoz Events, the founders of Global Titans, have teamed up with Web3 experts, MintGate for this NFT. Buyers will be able to watch the livestream of these inaugural fights directly from anywhere in the world without requiring access codes or passwords. NFT owners can simply connect their crypto wallets (such as MetaMask) for instant access.
Additionally, owners of this NFT will be able to unlock Limited Edition 3D collectibles, special video content and official media from the event.
There are two Global Titans NFT tickets now available to the public.
- 80,000 collectible NFTs with PPV access in the Polygon Matic or payable by credit card.
- Currently 10 highly exclusive ringside seat NFTs are available to attend this event in person.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream are available at www.globaltitans.com
“MintGate is hyper-focused on making digital ownership accessible to anyone in the world,” said Jonathan Dunlap (CEO). “To further this mission, we launched a revolutionary way to purchase a NFT directly with a credit card,” continued Matt Hoffman (CSO).
Robert Quirke, ROQUMedia (CEO) stated: “For many people, this will be the first time they will buy an NFT. We made sure to provide them with great value, by including exciting digital assets that can be traded and combined to watch the Floyd Mayweather fight livestream online. The live event on May 14th will be known as an international turning point where live sports and entertainment embraced the next generation of technology. The PPV tickets use the Polygon Blockchain & MATIC, as this offers fans the lowest gas fees, making them significantly more environmentally friendly.”
GLOBAL TITANS
Global Titans Dubai is the first in series of special boxing and MMA events which will be staged at iconic locations across four continents. Each main event is broadcast globally, featuring champion fighters and exclusive collectable NFT tickets.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream: www.globaltitans.com
MINTGATE
MintGate is a proven web3 platform for building membership-based communities and elevating the relationship between people and the brands they care about. We bring people closer to the future by unlocking the value of digital ownership.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005564/en/
Contact information
KATCH INTERNATIONAL
Sharanya Paulraj
Email:
sharanya@katchthis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom